A viral exposure signature (VES) has previously been shown to predict the development of hepatocellular carcinoma (HCC) in at-risk individuals through comprehensive serological profiling using the VirScan platform. Whether cumulative antimicrobial immune histories are associated with cancer status across multiple mal...
Beatrice Cavalluzzo, Biancamaria Cembrola, Simona Mangano et al.· Cell Death & Disease· 0 citations
A novel prognostic index for patients with locally advanced or metastatic biliary tract cancer treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab is explored and validated.
M. Persano, A. Casadei-Gardini, L. Fornaro et al.· Cancer· 0 citations
Body composition (BC) analysis may integrate assessment of nutritional risk in patients with gastrointestinal cancers. Applying unsupervised machine learning techniques, we derived BC profiles (BCPs) and investigated their association with malnutrition risk and quality of life. This cross-sectional analysis includes ga...
Assunta Luongo, F. D. Di Carlo, S. Coluccia et al.· Current Oncology· 0 citations
Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...
Davide Ciardiello, G. Martini, L. Boscolo Bielo et al.· The journal of liquid biopsy· 0 citations
First-line tislelizumab plus chemotherapy provided sustained and clinically meaningful efficacy benefits over placebo plus chemotherapy and was tolerable, with no new safety signals for patients with unresectable, locally advanced, or metastatic ESCC and PD-L1 TAP score ≥5%.
D. Tougeron, J. Xu, E. Raymond et al.· ESMO Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.